Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2012-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Previous studies have shown that people with certain types of brain damage may have particular problems paying attention and processing things that they see. Researchers are interested in comparing how people with brain damage and without brain damage process visual images.
Objectives:
\- To better understand the areas of the brain involved in paying attention to things that are seen.
Eligibility:
\- Individuals at least 18 years of age who either have had damage to one or both sides of specific parts of the brain (e.g., stroke, injury, certain neurosurgery procedures) or are healthy volunteers.
Design:
* The study involves 4 to 10 visits to the NIH Clinical Center over 1 to 2 years. Each visit will last approximately 2 hours.
* Participants will be screened with a medical history and physical examination, and may have the cognitive testing described below during the same visit.
* On the first visit and for at least one visit thereafter, participants will have cognitive testing to evaluate thinking and memory. These tests will be either written tests or computer-based tests.
* Some participants will qualify for functional magnetic resonance imaging (fMRI) as part of the study. This part will involve a decision-making task that will be performed on a computer during the fMRI scan. Additional scans may be required as directed by the study doctors.
* Some randomly selected participants will be asked to have magnetoencephalography (MEG), a procedure to record very small magnetic field changes produced by brain activity.
* During the behavioral training, or fMRI or MEG scanning, participants may be monitored with equipment to track eye movements.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
What is the source of this attentional modulation? Because neuroimaging studies have demonstrated that multiple cortical regions are recruited during tasks involving selective attention, it has proven difficult thus far to determine the differential contributions of each region. A central goal of the proposed research is to characterize the contributions of prefrontal cortex and parietal cortex and test the hypothesis that these regions exert top-down modulatory influences over visual processing areas. Specifically, we wish to investigate the interaction between areas involved in attentional control and visual areas modulated by attention.
We propose to study patients with focal lesions and healthy volunteers while they perform tasks requiring attention. Subjects will participate, first, in a series of behavioral studies involving selective attention; the relative performance of different patient groups and neurologically healthy volunteers will be compared. Subjects will also be studied while performing similar tasks during functional magnetic resonance imaging (fMRI). We hypothesize that selective attention will be heavily impaired by lesions of key prefrontal (e.g., dorsolateral prefrontal cortex) and key parietal (e.g., superior parietal lobule) sites. We also expect that brain imaging data will show decreased activation in visual regions ipsilateral to the focal lesions in prefrontal and parietal cortex, thus providing evidence that prefrontal and parietal cortex are sources of top-down modulation. Although other research groups have compared the behavior of patients with various focal lesions or have performed fMRI studies of visual attention in neurologically normal patients, we are unaware of any concerted effort to perform fMRI in patients with focal lesions in order to functionally isolate the contributions of individual cortical regions that serve as critical nodes in the attentional network.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Neurologically normal healthy volunteers in good general health.
No interventions assigned to this group
2
Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. All subjects will be 18 years of age or older and have at least a high school education.
2. Capacity to provide their own informed consent, understand and cooperate with study procedures.
3. Able to read and write in English to guarantee understanding of all written and spoken instructions, which are in English.
Patients:
1. Unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
2. At least three months post-stroke, lobectomy and or neurosurgical resection.
Healthy volunteers:
1\. Neurologically normal and in good general health.
Exclusion Criteria
1. Any neurological or psychiatric disorder not related to the focal lesion (e.g., epilepsy, schizophrenia, etc.). Epilepsy patients who have undergone surgery and as a result are seizure free may be recruited.
2. Previous head injury.
3. Present or past (within past 6 months) drug or alcohol abuse or addiction as determined by a qualified study neurologist/psychiatrist.
4. Radiation treatment to the brain during a three-month period prior to the experiment.
Healthy volunteers:
1. Any neurological or psychiatric disorder (e.g., epilepsy, schizophrenia, etc.)
2. Previous head injury.
3. Present or past (within past 6 months) drug or alcohol abuse or addiction based on DSM-5 criteria as determined during History and Physical exam.
Patients and Healthy volunteers:
1. Women who are pregnant and women of child-bearing potential who refuse to undergo a urine pregnancy test will be excluded from fMRI experiments.
2. Subjects who have contraindications to MRI scanning will be excluded from fMRI experiments but included in cognitive experiments. These contraindications include:
1. central nervous system aneurysm clips;
2. implanted neural stimulator;
3. implanted cardiac pacemaker or defibrillator;
4. cochlear implant;
5. ocular foreign body (e.g., metal shavings);
6. insulin pump;
7. metal shrapnel or bullet;
8. any implanted device that is incompatible with MRI.
3. Conditions that preclude scanning, e.g., morbid obesity, claustrophobia.
Patients and Healthy volunteers:
Subjects who are determined during screening or history and physical exam to be color-blind will be excluded from participating in certain tasks that involve color discrimination.
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shruti A Japee, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, Hyde JS. Time course EPI of human brain function during task activation. Magn Reson Med. 1992 Jun;25(2):390-7. doi: 10.1002/mrm.1910250220.
Belliveau JW, Kennedy DN Jr, McKinstry RC, Buchbinder BR, Weisskoff RM, Cohen MS, Vevea JM, Brady TJ, Rosen BR. Functional mapping of the human visual cortex by magnetic resonance imaging. Science. 1991 Nov 1;254(5032):716-9. doi: 10.1126/science.1948051.
Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988 Jul 22;241(4864):462-4. doi: 10.1126/science.3260686.
Gilmore AW, Audrain S, Snow J, Gollomp E, Wilson JM, Agron AM, Hammoud DA, Butman JA, Martin A. Long-term retention of real-world experiences in a patient with profound amnesia. Neuropsychologia. 2024 Nov 5;204:109010. doi: 10.1016/j.neuropsychologia.2024.109010. Epub 2024 Oct 9.
Zhang H, Japee S, Nolan R, Chu C, Liu N, Ungerleider LG. Face-selective regions differ in their ability to classify facial expressions. Neuroimage. 2016 Apr 15;130:77-90. doi: 10.1016/j.neuroimage.2016.01.045. Epub 2016 Jan 28.
Hansen KA, Chu C, Dickinson A, Pye B, Weller JP, Ungerleider LG. Spatial selectivity in the temporoparietal junction, inferior frontal sulcus, and inferior parietal lobule. J Vis. 2015;15(13):15. doi: 10.1167/15.13.15.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-M-0047
Identifier Type: -
Identifier Source: secondary_id
100047
Identifier Type: -
Identifier Source: org_study_id